Please assess the completion status of the following clinical trial:

Trial Title: Comparison of MAG and Fish Oil Efficacy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65~* Sex female~* Body Mass Index (BMI) ≥ 30kg/m2 and \< 40kg/m2~* Subjects willing to undergo treatment with Orlistat® (Xenical).~* Having obtained her written informed consent before any study related procedure including the pre-inclusion period.~Subject exclusion criteria:~* Binge eating disorder~* Any other weight loss treatment(s) within the last 3 months~* Vegetarians~* History of metabolic, cardiovascular, hepatic or renal diseases~* Obstructed bile duct~* Diseases that could interfere with intestinal absorption History of abdominal / gastric surgery (except appendicectomy)~* Use of drugs or illicit substances~* Consumption of alcohol \> 50 gr/week~* Any other clinically significant abnormalities on screening laboratory evaluation (creatinine, Na, K, urique acide, ASAT, ALAT, Ph. Alc., yGT, Glycemia, total cholesterol, HDL, LDL, triglycerides) concentrations \> 2.5 fold normal range~* Pregnant or lactating mothers~* Allergy to fish oil or other components (for e.g., gelatin or excepients of the capsule)~* Use of any other supplements containing fish oil for the duration of the trial or 3 month before inclusion in trial.~* Smokers~* Having donated blood or had a transfusion of blood/blood products during the trial and 3 months prior to screening or expected to do so during the study~* Bleeding disorders~* Subject who cannot be expected to comply with the study procedures.~* Currently participating or having participated in another clinical trial during last 8 weeks prior to the beginning of this study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Fish oil enriched with EPA + ORLISTAT (Type: ACTIVE_COMPARATOR): The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.~The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
- MAG-EPA (Type: ACTIVE_COMPARATOR): The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
- MAG-EPA + ORLISTAT (Type: ACTIVE_COMPARATOR): The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.~The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
- Fish oil enriched with EPA (Type: ACTIVE_COMPARATOR): The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete